Pelargonidin (PEL) is a well-known red pigment found in plants and has important biological activities that are potentially beneficial for human health. The aim of this study was to investigate the effect of PEL on lipopolysaccharide (LPS)-induced liver failure in mice, and to elucidate its underlying molecular mechanisms. Liver failure was induced by LPS (15 mg/kg, i.p.) in mice, and 12 h later, they were treated intravenously with PEL. Administration of LPS significantly increased mortality, serum levels of alanine transaminase (ALT), aspartate transaminase (AST), and inflammatory cytokines, and expression of toll-like receptor 4 (TLR4) protein; PEL treatment effectively countered these effects of LPS. Further, LPS treatment markedly increased the expression of myeloid differentiation primary response gene 88 (MyD88), phosphorylation of p38, extracellular signal-regulated kinase (ERK), and c-Jun N-terminal kinase (JNK), and expressions of nuclear proteins, such as nuclear factor (NF)-B and phosphorylated c-Jun. Additionally, LPS increased the serum levels of tumor necrosis factor (TNF)-α and interleukin (IL)-6. All these effects of LPS were attenuated by PEL. In addition, the LPS-mediated increase in the level of serum interferon (IFN)-β expression of the TLR-associated activator of IFN (TRIF) protein, and phosphorylation of IFN regulatory factor 3 (IRF3) were reduced by PEL. Our results suggest that PEL attenuates LPS-induced liver damage by inhibition of the TLR-mediated inflammatory pathway and could be used to treat liver diseases.
Hepatic injury initiates and causes numerous liver diseases that progress to terminal liver failure [1] . Chronic hepatic injury often leads to liver fibrosis, cirrhosis, and even, liver cancer, and these diseases have a serious impact on the body [1] . Hepatic injury seriously threatens human health and is a cause for extensive concern [1] [2] . Bacterial lipopolysaccharide (LPS) is present on the outer membranes of all gram-negative bacteria and causes the systemic inflammatory response syndrome and septic shock, which finally lead to multi-organ failure [3] . LPS-induced lethality is characterized by liver failure, accompanied by severe hepatic injury [3] [4] . LPS has been used to create experimental models to analyze the mechanism of endotoxin-induced hepatic injury [3] [4] .
Pelargonidin (PEL) and its glucoside form (pelargonidin-3-glucoside, P3G), have been found in red, purple, and blue colored vegetables and fruits; PEL has antioxidant and antidiabetic activities in vivo [5] [6] [7] [8] [9] . Recently, PEL and P3G have been reported to have anti-inflammatory and anti-carcinogenic activities along with being effective in preventing cardiovascular diseases and managing diabetes [10] [11] . However, to the best of our knowledge, the effects of PEL on LPS-induced hepatic injury have not been previously determined. We hypothesized that exogenous PEL treatment may modulate the development of LPS-induced hepatic injury and investigated the underlying mechanisms of hepatoprotective effects of PEL on LPS-induced increase in lethality, elevated serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and inflammatory cytokines.
LPS-induced hepatic failure in mice has been widely used as an in vivo model that closely mimics the cascade of events leading to clinical hepatitis caused by endotoxemia and sepsis [3, 4] . Based on the reported anti-inflammatory and anti-carcinogenic activities of PEL [10, 11] , we hypothesized that PEL would ameliorate LPSinduced lethality in mice. Lethality was not observed in mice in the control group. However, mice in the LPS group began to die 24 h after LPS injection. The survival rate was 80% at 24 h and reached 0% at 96 h after LPS injection. Post-treatment with PEL (0.2, 0.4, or 0.6 mg/kg, i.v.) reduced the mortality in a dose-dependent manner, as observed in the Kaplan-Meier survival analysis (p < 0.0001; Figure 1 ). Interestingly, P3G did not reduce LPS-induced lethality in mice. Therefore, PEL at 0.6 mg/kg was selected as the optimal effective dose for investigating the molecular mechanisms of PEL against LPS-induced hepatotoxicity.
Further, we determined the effects of PEL or P3G on serum levels of hepatic injury markers, such as ALT and AST ( Table 1 ). The serum levels of ALT and AST in the control group were 5.9 ± 0.4 and 16.2 ± 0.9 U/L, respectively, and were not affected by PEL or NPC Natural Product Communications Table 1 : Effect of PEL on serum levels of ALT, AST, TNF-α, IL-6, and IFN-β. Mice were intravenously administered vehicle, PEL (0.6 mg/kg), or P3G (0.96 mg/kg) 12 h after LPS administration. Liver damage was assessed at 48 h after LPS administration by measurement of circulating serum ALT and AST levels. Serum levels of TNF-α, IL-6 and IFN-β were measured using commercially available ELISA kits at 48 h after LPS administration. Results are represented as the mean ± SD (n = 5). *p < 0.01 versus LPS group. P3G treatments alone. At 48 h after LPS injection, the levels of serum ALT and AST markedly increased to 61.2 ± 4.4 and 105.4 ± 8.6 U/L, respectively. The increase in these levels was suppressed by PEL treatment (0.6 mg/kg, i.v.). The liver tissues of mice in the control, PEL, and P3G groups exhibited normal lobular and cellular architecture ( Figure 2 ). However, extensive areas of portal inflammation, parenchymal necrosis, moderate infiltration of inflammatory cells, and severe hemorrhagic necrosis that were observed in the LPS group were markedly less visible in the LPS + PEL (0.6 mg/kg, i.v.) group (Figure 2 ). These results suggested that PEL suppresses the lethality of hepatic injury and holds potential in the clinical treatment of liver diseases.
However, P3G did not reduce the levels of ALT and AST (Table 1) , and other markers of liver injury ( Figure 2 ). Natural flavonoids are commonly found as 3-and 7-O-glycosides [12, 13] . Generally, the glycoside flavonoids are hydrolyzed in the dietary tract and absorbed as aglycones in vivo [14] . These flavonoid aglycones function as bioactive compounds [13] . In addition, it has been reported that the glucose moiety in flavonoids interferes with their interaction with proteins [13] . Therefore, the 3-o-glycosylation on P3G can be speculated to reduce its bioactivity and thereby, its hepatoprotective effect.
TLR4 is the recognition receptor for LPS, which is involved in eliciting a microbial immune response and cell activation [15] . A number of studies have reported the role of TLR4 in inflammatory diseases [15] [16] [17] . Therefore, we determined the effects of PEL on LPS-induced TLR4 protein expression. At 48 h after LPS injection, the level of TLR4 protein expression increased to approximately 8.4-fold of that of the control group. This increase was attenuated by post-treatment with PEL (0.6 mg/kg, i.v.) as shown in Figure 3 , suggesting that the hepatoprotective effects of PEL might be associated with its inhibition of TLR4 overexpression. TLR signaling by LPS activation involves the MyD88-dependent pathway, which results in the expression of inflammatory genes, such as TNF-α and IL-6 [18, 19] . MyD88 is a common adaptor molecule leading to the activation of NF-B and MAPKs [18] .It is well known that MAPK activation is involved in eliciting the LPSinduced hyper-inflammatory response, and inhibitors of MAPKs have demonstrated therapeutic potential for the treatment of inflammatory diseases [20] . Furthermore, a significant reduction in hepatic NF-B activation has been reported in TLR4-knockout mice following LPS induction of hepatic failure [21] . Therefore, in this study, we tested the effects of PEL on LPS-mediated MyD88 protein expression and the activation of MAPKs, including p38, ERK, and JNK, and the expression of nuclear proteins, such as NF-B and p-c-Jun (Table 2) . At 48 h after LPS injection, the level of MyD88 protein expression increased to 3.52-fold of that in the control group. Moreover, the phosphorylation of p38, ERK, and JNK increased to 2.2-, 2.2-, and 2.9-fold, respectively, of those in the control group. We evaluated the activation of NF-B by measuring the NF-B/p65 subunit protein level in the nucleus. To elucidate the mechanism of NF-B activation during LPS-induced hepatotoxicity and its modulation by PEL, the cytosolic protein levels of IB-, an endogenous NF-B inhibitor, were also quantified. The nuclear level of the p65 subunit increased to 2.39-fold of that in the control group, and this increase was attenuated by PEL. Consistent with this result, the cytosolic level of IB-α decreased in the LPS group, and treatment with PEL attenuated this decrease. The nuclear protein level of p-c-Jun in the LPS group increased to 2.41-fold of that in control group, and the increase in pc-Jun was attenuated by PEL ( Table 2 ). The levels of serum TNF-α and IL-6 in the control group were 98.5 ± 8.32 and 125.8 ± 10.3 pg/mL, respectively, which increased to 653.3 ± 52.5 and 358.2 ± 24.6 pg/mL, respectively, after LPS injection. These increases were attenuated by PEL and indicating that the MyD88-dependent signaling pathway was suppressed, thereby preventing the activation of MAPK and production of inflammatory gene products in LPS-induced hepatic failure.
TLR signaling by LPS activation involves the MyD88-dependent pathway, which results in the expression of inflammatory genes, such as TNF-α and IL-6 [18, 19] . MyD88 is a common adaptor molecule leading to the activation of NF-B and MAPKs [18] . It iswell known that MAPK activation is involved in eliciting theLPSinduced hyper-inflammatory response, and inhibitors of MAPKs have demonstrated therapeutic potential for the treatment ofinflammatory diseases [20] . Furthermore, a significant reduction in hepatic NF-B activation has been reported in TLR4-knockout mice following LPS induction of hepatic failure [21] . Therefore, in this study, we tested the effects of PEL on LPS-mediated MyD88 protein expression and the activation of MAPKs, including p38, ERK, and JNK, and the expression of nuclear proteins, such as NF-B and p-c-Jun (Table 2) . At 48 h after LPS injection, the level
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Natural Product Communications Vol. 13 (1) 2018 47 Table 2 : Effect of PEL on MyD88 protein expression and activation of MAPKs and NF-B. MyD88 protein expression and p38, ERK, and JNK activation in the liver were measured by ELISA at 48 h after LPS treatment. NF-B and p-c-Jun were assayed using the nuclear extracts from liver at 48 h after LPS treatment. IB-α was measured in the cytosolic extracts from liver at 48 h after LPS treatment. Results are normalized to the untreated control and represented as the mean ± SD (n = 5). *p < 0.01 versus LPS group.
of MyD88 protein expression increased to 3.5-fold of that in the control group. Moreover, the phosphorylation of p38, ERK, and JNK increased to 2.2-, 2.2-, and 2.9-fold, respectively, of those in the control group. We evaluated the activation of NF-B by measuring the NF-B/p65 subunit protein level in the nucleus. To elucidate the mechanism of NF-B activation during LPS-induced hepatotoxicity and its modulation by PEL, the cytosolic protein levels of IB-, an endogenous NF-B inhibitor, were also quantified. The nuclear level of the p65 subunit increased to 2.39-fold of that in the control group, and this increase was attenuated by PEL. Consistent with this result, the cytosolic level of IB-α decreased in the LPS group, and treatment with PEL attenuated this decrease. The nuclear protein level of p-c-Jun in the LPS group increased to 2.41-fold of that in control group, and the increase in pc-Jun was attenuated by PEL ( Table 2 ). The levels of serum TNF-α and IL-6 in the control group were 98.5 ± 8.3 and 125.8 ± 10.2 pg/mL, respectively, which increased to 653.3 ± 52.5 and 358.2 ± 24.5 pg/mL, respectively, after LPS injection. These increases were attenuated by PEL and indicating that the MyD88-dependent signaling pathway was suppressed, thereby preventing the activation of MAPK and production of inflammatory gene products in LPS-induced hepatic failure. TRIF, another adaptor protein of TLRs, is responsible for modulation of the MyD88-independent pathway [22] . It activates downstream kinases, such as IB kinase (IKK)and TRIF-binding kinase 1 (TBK1), which results in the phosphorylation of IRF3 and expression of type 1 IFNs and IFN-inducible genes [23] . Therefore, we determined the effect of PEL on the expression of TRIF, phosphorylation of IRF3, and level of serum IFN-β after LPS stimulation. Data showed that at 48 h after LPS injection, the level of TRIF protein expression and IRF3 phosphorylation increased to 3.3-and 7.7-fold of those in the control group; these increases were suppressed by PEL (Figure 4) . The level of serum IFN-β in the control group was 42.5 ± 3.2 pg/mL, whereas after LPS injection, the level of serum IFN- increased to 108.6 ± 9.3 pg/mL, and this increase was attenuated by PEL (Table 1) . Taken together, our results indicated that both MyD88-and TRIF-dependent signaling pathways of the TLR system are activated in hepatic failure by LPS, and suppressive effects of PEL on these signaling pathways contribute to its hepatoprotective effects.
In conclusion, activation of MyD88-and TRIF-dependent signaling pathways of the TLR system by LPS is involved in the pathogenesis of hepatic failure, and PEL represents a potent pharmacological intervention to ameliorate hepatic injury through inhibition of the TLR signaling pathways. This approach utilizing PEL allows modulation of the immune system to reduce local inflammation.
Experimental
Reagents: PEL, P3G, and bacterial LPS were obtained from Sigma (St. Louis, MO). Male C57BL/6 mice (6 weeks old) were administered an approximately 70% lethal dose of endotoxin (15 mg/kg i.p.) [24] .
Animals and husbandry:
Male C57BL/6 mice (6 weeks old, weighing 27 g) were purchased from Orient Bio Co. (Sungnam, Republic of Korea). All the mice were treated in accordance with the "Guidelines for the Care and Use of Laboratory Animals," which were issued by Kyungpook National University (IRB No. KNU 2016-54). Hematoxylin & Eosin staining and histopathological examination: Liver tissues were isolated from a portion of the left lobe, washed thrice in PBS (pH 7.4) to remove remaining blood, and fixed in 4% formaldehyde (Junsei, Japan) in PBS (pH 7.4) for 20 h at 4°C. After fixation, the samples were dehydrated, deparaffinized, and counterstained with eosin (Sigma), and prepared slides were analyzed under light microscopy by a blinded observer to observe hepatocyte architecture, tissue edema, and infiltration of the inflammatory cells, as previously described [25] .
LPS-induced lethal endotoxemia model:
Isolation of nuclear and cytosolic proteins and western blotting analysis: NE-PER™ nuclear and cytoplasmic extraction reagents (Thermo Fisher Scientific, Waltham, MA) were used for extracting nuclear and cytosolic proteins. Equal amounts of protein (20 µg) were separated by SDS-PGAE (10%) and electroblotted overnight onto Immobilon membranes (Millipore, Billerica, MA). They were then incubated with primary antibodies against toll-like receptor 4 (TLR4, Santa Cruz Biotechnology, Santa Cruz, CA), TLRassociated activator of IFN (TRIF), p-IFN regulatory factor 3 (IRF3, Abcam, UK), or β-actin (Santa Cruz Biotechnology) at room 48 Natural Product Communications Vol. 13 (1) 2018 Lee et al.
temperature for 1.5 h; this was followed by incubation with a horseradish peroxidase-conjugated secondary antibody and ECL detection, according to the manufacturers' instructions.
Statistical analyses:
All experiments were independently performed at least three times and the values are expressed as mean ± SD. The Student's t-test was used to calculate significant differences and statistical significance was accepted at p-values < 0.05. SPSS for Windows, version 16.0 (SPSS, Chicago, IL) was used to perform all statistical analyses.
